Literature DB >> 35533213

Asymmetric De Novo Synthesis of a Cucurbitane Triterpenoid: Total Synthesis of Octanorcucurbitacin B.

Andrea R Bucknam1, Glenn C Micalizio1.   

Abstract

The asymmetric de novo synthesis of a cucurbitane natural product, octanorcucurbitacin B, has been accomplished. Cucurbitanes are a family of structurally complex triterpenoids that characteristically contain three stereodefined quaternary centers at ring fusion carbons positioned about their tetracyclic skeletons (at positions 9, 13, and 14). Taking a diversion from the biosynthetic hypothesis for cucurbitane synthesis, the approach established here provides direct access to the cucurbitane skeleton without having to proceed by way of a lanostane. Using a simple chiral enyne as starting material, a sequence of annulative cross-coupling and intramolecular Heck reaction provides a stereodefined polyunsaturated tetracycle possessing the C9 and C13 quaternary centers. This intermediate was converted to octanorcucurbitacin B through a 12-step sequence that features hydroxy-directed Simmons-Smith cyclopropanation, regioselective deconjugative alkylation, and allylic oxidation.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35533213      PMCID: PMC9410570          DOI: 10.1021/jacs.2c03109

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   16.383


  23 in total

1.  Lipid-Lowering Activities of Cucurbitacins Isolated from Trichosanthes cucumeroides and Their Synthetic Derivatives.

Authors:  Xianjing Zhang; Huihui Li; Wenqiong Wang; Tong Chen; Lijiang Xuan
Journal:  J Nat Prod       Date:  2020-12-03       Impact factor: 4.050

2.  Synthesis of hemslecin A derivatives: a new class of hepatitis B virus inhibitors.

Authors:  Rui-Hua Guo; Chang-An Geng; Xiao-Yan Huang; Yun-Bao Ma; Quan Zhang; Li-Jun Wang; Xue-Mei Zhang; Rong-Ping Zhang; Ji-Jun Chen
Journal:  Bioorg Med Chem Lett       Date:  2013-01-16       Impact factor: 2.823

Review 3.  Cucurbitacin B and cancer intervention: Chemistry, biology and mechanisms (Review).

Authors:  Sukant Garg; Sunil C Kaul; Renu Wadhwa
Journal:  Int J Oncol       Date:  2017-11-10       Impact factor: 5.650

Review 4.  Cucurbitacins and cucurbitane glycosides: structures and biological activities.

Authors:  Jian Chao Chen; Ming Hua Chiu; Rui Lin Nie; Geoffrey A Cordell; Samuel X Qiu
Journal:  Nat Prod Rep       Date:  2005-04-04       Impact factor: 13.423

5.  Design, synthesis and biological evaluation of mogrol derivatives as a novel class of AMPKα2β1γ1 activators.

Authors:  Junwei Wang; Junhua Liu; Zhifu Xie; Jia Li; Jingya Li; Lihong Hu
Journal:  Bioorg Med Chem Lett       Date:  2019-11-09       Impact factor: 2.823

6.  Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.

Authors:  Jessica A Hall; Sahithi Seedarala; Nichole Rice; Lucas Kopel; Fathi Halaweish; Brian S J Blagg
Journal:  J Nat Prod       Date:  2015-03-10       Impact factor: 4.050

7.  From Metallacycle-Mediated Annulative Cross-Coupling to Steroidal Tetracycles through Intramolecular C9-C10 Bond Formation.

Authors:  Adam B Millham; Chinmay P Bhatt; Glenn C Micalizio
Journal:  Org Lett       Date:  2020-08-12       Impact factor: 6.005

8.  Octanorcucurbitane and cucurbitane triterpenoids from the tubers of Hemsleya endecaphylla with HIV-1 inhibitory activity.

Authors:  Jian-Chao Chen; Gao-Hong Zhang; Zhong-Quan Zhang; Ming-Hua Qiu; Yong-Tang Zheng; Liu-Meng Yang; Kai-Bei Yu
Journal:  J Nat Prod       Date:  2007-12-19       Impact factor: 4.050

9.  Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer.

Authors:  Mohammed Sikander; Bilal Bin Hafeez; Shabnam Malik; Abdulrhman Alsayari; Fathi T Halaweish; Murali M Yallapu; Subhash C Chauhan; Meena Jaggi
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

10.  Synthesis of cucurbitacin IIa derivatives with apoptosis-inducing capabilities in human cancer cells.

Authors:  Kun Yu; Xinmei Yang; Ying Li; Xue Cui; Bo Liu; Qingqiang Yao
Journal:  RSC Adv       Date:  2020-01-23       Impact factor: 4.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.